Skip to main
  1. Stocks
  2. Gilead Sciences
  3. Forecast
GILD

Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences (GILD) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 53%
Buy 29%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Gilead Sciences is viewed positively because its core HIV franchise is delivering unusually strong momentum, with 3Q26 HIV sales of $6.25B and management raising FY26 HIV growth guidance to 12% from 9%-10%, supported by Biktarvy leadership and Yeztugo’s $305M launch traction. The company’s broader fundamentals are also improving as PrEP demand and channel mix lift revenue, total FY26 product sales guidance rises to $31.0-$31.3B, and durable cash generation is reinforced by $6.4B in cash and $5.0B in 3Q26 operating cash flow. Beyond HIV, Trodelvy is expanding in oncology, Yescarta/Tecartus infrastructure supports anito-cel, and a growing inflammation pipeline plus tuck-in acquisitions adds long-term diversification and optionality.

Bears say

Gilead Sciences is exposed to several fundamental pressures that support a negative outlook, led by generic HIV entrants, competition in HCV, and greater-than-expected pricing pressure across its core franchises. Its growth thesis also depends on newer assets, yet slower Yescarta uptake, failure to expand its label, or setbacks in oncology programs such as Trodelvy could leave estimates vulnerable, while legal and patent risks add further uncertainty. The company also faces potential cuts in federal HIV spending, clinical trial misses or safety concerns, and broader macro weakness, any of which could weigh on revenue durability and execution.

Gilead Sciences (GILD) has been analyzed by 17 analysts, with a consensus rating of Buy. 53% of analysts recommend a Strong Buy, 29% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.

Gilead Sciences (GILD) Analyst Forecast & Price Prediction

Get the latest Gilead Sciences (GILD) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Gilead Sciences (GILD)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gilead Sciences (GILD) Forecast

Analysts have given Gilead Sciences (GILD) a Buy based on their latest research and market trends.

According to 17 analysts, Gilead Sciences (GILD) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $175.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $175.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gilead Sciences (GILD)


Gilead Sciences (GILD) Analyst Forecast & Price Prediction

Get the latest Gilead Sciences (GILD) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Gilead Sciences (GILD)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover GILD stock data and trends